Friday, October 16, 2026

Workday's Bundled AI Agents Drive 50% Larger Expansion Deals Than Separate SKUs

Workday's expansion deals that include AI components are more than 50% larger on average than those without. New annual contract value from agentic AI products grew 200% year-over-year. Customer adoption of Workday's natively built AI agents more than doubled quarter-over-quarter.

LM Salvado

May 25, 2026

Workday's Bundled AI Agents Drive 50% Larger Expansion Deals Than Separate SKUs
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Workday's expansion deals that include AI components are over 50% larger on average than deals without them.1 The data makes a pointed case for embedding AI directly into SaaS platforms rather than selling it as a standalone product.

New annual contract value from Workday's agentic AI products grew 200% year-over-year.1 Customers using the company's organically developed AI agents more than doubled in a single quarter.1

The pattern challenges a common enterprise software assumption: that AI is best monetized as a discrete add-on. Workday's numbers suggest the opposite. When AI reduces steps in existing workflows, buyers spend more and adopt faster.

Workday's unified pricing model, built around flex credits, is seeing growing adoption.1 The approach bundles AI consumption into a single currency across the platform, removing per-feature pricing friction. That simplification appears to accelerate both initial deals and expansions.

The embedded model works because it meets buyers where they already operate. Deploying agents inside HR, finance, or procurement workflows eliminates integration timelines and reduces the evaluation burden on IT. Time-to-value compresses.

Agentic AI — systems that take multi-step actions autonomously — differs from earlier AI features like summarization or search. Agents can initiate workflows, route approvals, and act on data without human triggers. Bundled into existing SaaS, they extend platform stickiness while surfacing measurable productivity gains buyers can point to in renewal conversations.

The hypothesis that bundled AI drives meaningfully larger deal sizes than separate SKUs remains formally untested across the broader SaaS market. Whether Salesforce, ServiceNow, or SAP replicate Workday's trajectory over the next four quarters will determine if this is a repeatable playbook or a company-specific result. But Workday's early numbers are hard to ignore: 200% ACV growth and deals half again as large when AI is in the package.

For enterprise software buyers, the implication is practical. Platforms that bundle agents natively lower the switching cost of adoption. The AI is already there — the question becomes whether to activate it, not whether to buy it separately.

In this story

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com